Hyperphosphatemia, the elevation of serum phosphate levels, is a nearly universal complication in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) on dialysis. It is a critical contributor to the development of mineral and bone disorder (CKD-MBD) and is strongly associated with increased cardiovascular calcification, morbidity, and mortality. The cornerstone of managing hyperphosphatemia involves dietary phosphate restriction and the use of oral phosphate-binding agents. Among these, sevelamer has emerged as a significant therapeutic option since its introduction in the late 1990s, distinguished by its non-calcium, non-metal composition. This article reviews the pharmacology, clinical efficacy, safety profile, and potential pleiotropic effects of sevelamer in the management of CKD-associated hyperphosphatemia.
Pharmacology and Mechanism of Action
Sevelamer is a non-absorbed, hydrophilic, cross-linked polymer. It is available in two primary salt forms: Monografia Evidenze-Based sevelamer hydrochloride and sevelamer carbonate; the latter was developed to mitigate the potential for metabolic acidosis associated with the hydrochloride formulation. Unlike traditional calcium-based binders or aluminum salts, sevelamer contains no calcium or metal ions. Its mechanism of action is purely local within the gastrointestinal tract. The polymer carries multiple amine groups separated by one carbon from the polymer backbone, which are partially protonated at physiological pH. These positively charged sites bind to dietary phosphate anions through ionic and hydrogen bonding, forming a non-absorbable complex that is excreted in the feces. By sequestering phosphate in the gut, sevelamer reduces the intestinal absorption of dietary phosphate, thereby lowering serum phosphate concentrations. It does not alter the absorption of other electrolytes like sodium, potassium, or chloride to a clinically significant degree.
Clinical Efficacy
Numerous randomized controlled trials and observational studies have established the efficacy of sevelamer in lowering serum phosphate and serum calcium-phosphate product in dialysis patients to a degree comparable to calcium-based binders. The pivotal Treat-to-Goal study demonstrated that sevelamer was as effective as calcium acetate in controlling hyperphosphatemia but was associated with a significantly lower incidence of hypercalcemic episodes. This is a crucial distinction, as hypercalcemia from calcium-based binders can exacerbate vascular calcification.
Perhaps the most significant area of investigation has been sevelamer’s impact on cardiovascular calcification. The aforementioned Treat-to-Goal trial and the RIND study used coronary artery calcium scoring via electron-beam computed tomography. Both found that patients treated with sevelamer had less progression of coronary and aortic calcification over 12-18 months compared to those treated with calcium-based binders, despite similar phosphate control. This suggests that the choice of phosphate binder may independently influence vascular health beyond mere phosphate lowering, likely by avoiding positive calcium balance.
Furthermore, sevelamer has been shown to exert beneficial effects on lipid profiles. As a bile acid sequestrant analog, it binds to bile acids in the intestine, interrupting the enterohepatic circulation and leading to increased hepatic conversion of cholesterol into bile acids. This results in a modest but significant reduction in low-density lipoprotein cholesterol (LDL-C) and total cholesterol, and an increase in high-density lipoprotein cholesterol (HDL-C). While the clinical impact of this effect in the dialysis population, which often has complex dyslipidemia, is not fully defined, it represents a potential additional cardiovascular benefit.
Safety and Tolerability
The safety profile of sevelamer is generally favorable, particularly regarding the avoidance of hypercalcemia and aluminum toxicity. The most common adverse effects are gastrointestinal, including constipation, diarrhea, dyspepsia, nausea, and abdominal pain. These are often mild to moderate and may improve with dose adjustment or administration with meals. The switch from the hydrochloride to the carbonate formulation has reduced the risk of exacerbating metabolic acidosis, a common problem in CKD. However, clinicians should remain vigilant, especially in patients with pre-existing acidosis or low bicarbonate levels.
A notable concern with sevelamer is its potential to bind to other concurrently administered oral medications, potentially reducing their bioavailability. Drugs with a narrow therapeutic index, such as warfarin, digoxin, and levothyroxine, are of particular concern. It is recommended that patients take other medications at least one hour before or three hours after sevelamer to minimize this interaction.
While sevelamer is not absorbed, cases of rare but serious intestinal complications, including ileus, bowel obstruction, and perforation, have been reported, predominantly in patients with significant underlying gastrointestinal disorders, dysphagia, or those taking multiple medications that affect gut motility. Careful patient selection and monitoring are advised.
Pleiotropic Effects and Ongoing Research
Beyond phosphate and lipid control, research has explored other potential “pleiotropic” effects of sevelamer. Its anion-exchange properties allow it to bind other substances, including endotoxins and inflammatory mediators like lipopolysaccharide (LPS). Some studies suggest sevelamer may reduce systemic inflammation, a key driver of cardiovascular disease in CKD, by binding gut-derived uremic toxins and LPS. However, clinical data on hard outcomes from this effect remain inconclusive.
Sevelamer may also influence fibroblast growth factor 23 (FGF23), a phosphaturic hormone that is markedly elevated in CKD and independently associated with adverse outcomes. Some evidence indicates sevelamer may lower FGF23 levels more effectively than calcium-based binders, though this finding is not entirely consistent across studies.
Ongoing research continues to refine the role of sevelamer. This includes its use in earlier stages of CKD (pre-dialysis), where controlling phosphate and FGF23 earlier in the disease course might slow progression and prevent complications. Studies are also evaluating its potential benefits in patient populations beyond CKD, such as in managing hyperphosphatemia in pediatric patients or in conditions like tumoral calcinosis.
Conclusion
Sevelamer represents a cornerstone in the modern pharmacological armamentarium against hyperphosphatemia in CKD. Its efficacy in lowering serum phosphate is well-established, but its true value lies in its unique profile: it avoids the risks of calcium and metal accumulation, attenuates the progression of vascular calcification, and offers modest lipid-lowering benefits. While gastrointestinal side effects and drug interactions require mindful management, its overall safety profile is robust. The choice between sevelamer, calcium-based binders, and newer agents like lanthanum or iron-based binders should be individualized, considering serum calcium, vascular calcification burden, comorbidities, cost, and patient tolerance. As our understanding of CKD-MBD evolves, sevelamer’s role as a non-calcium binder that may confer benefits beyond phosphate control ensures its continued relevance in improving the long-term outcomes of patients with kidney disease.
